Q3 2024 INmune Bio Inc Earnings Call Transcript
Key Points
- INmune Bio Inc (INMB) successfully closed enrollment for its global Phase II trial of XPro in Alzheimer's disease, marking a significant milestone.
- The company demonstrated strong operational capabilities by managing a complex clinical trial across 8 countries and 30 sites.
- INKmune, a novel NK-focused cancer program, showed consistent immunologic effects and an excellent safety profile in its Phase I/II trial for metastatic castrate-resistant prostate cancer.
- INmune Bio Inc (INMB) raised $13 million in gross proceeds from a registered direct equity offering, strengthening its financial position.
- The company has sufficient cash to fund operations into the third quarter of 2025, providing financial stability for ongoing and future projects.
- Net loss attributable to common stockholders increased to approximately $12.1 million for the quarter, compared to $8.6 million in the same period last year.
- Research and development expenses rose significantly to $10.1 million, up from $6 million in the previous year, indicating increased spending.
- The company faces challenges in patient enrollment for its Alzheimer's trial due to the need for specific inflammatory biomarkers.
- There is uncertainty regarding the regulatory pathway for XPro, particularly concerning the use of biomarkers in a potential Phase III trial.
- INmune Bio Inc (INMB) has no deep-seated business development discussions in place, with potential partnerships likely hinging on future data outcomes.
Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio.
David?
Thank you, Chloe, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio's Third Quarter 2024 financial results. With me on the call today are Dr. RJ Tesi, CEO and Co-Founder of INmune Bio; Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio; and Dr.
CJ Barnum, our Head of Neuroscience. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
